Abby Hardy, Author at BioTuesdays

Developments

Aridis Pharma gets EMA orphan drug designation for CF drug

Aridis Pharmaceuticals (NASDAQ:ARDS) received European Medicines Agency (EMA) orphan drug designation for AR-501 for the treatment of lung infections in patients with cystic fibrosis (CF). AR-501 is an inhaled...

July 19, 2019

Developments

Alphatec launches titanium interbody implant for spinal fusion surgeries

Alphatec Holdings (NASDAQ:ATEC) launched its IdentiTi porous titanium interbody implant system for anterior lumbar interbody fusion procedures. Key features of the implant include a stiffness similar to bone, reduced...

July 19, 2019

Markets

Roth starts Akero Therapeutics at buy; PT $34

Roth Capital Partners initiated coverage of Akero Therapeutics (NASDAQ:AKRO) with a “buy” rating and price target of $34. The stock closed at $19.88 on July 12. “Although Akero’s lead asset, AKR-001 (a FGF21...

July 15, 2019

Executive Moves

Rahul Sarugaser joins Raymond James’ life sciences research team

Rahul Sarugaser Rahul Sarugaser has joined Raymond James’ Canadian equity research team as managing director, equity analyst, healthcare, biotechnology & cannabis. Most recently, Mr. Sarugaser was an equities...

July 12, 2019

Markets

Stifel ups Rhythm Pharma to buy; PT held at $34

Stifel upgraded Rhythm Pharmaceuticals (NASDAQ:RYTM) to “buy” from “hold” but maintained its price target at $34, saying the stock is at an attractive entry point ahead of near-term Phase 3 results. The stock closed at...

July 12, 2019

Developments

Trovagene initiates Phase 1b/2 trial of ovansertib in colorectal cancer

Trovagene (NASDAQ:TROV) began enrollment for its Phase 1b/2 study of onvansertib for the treatment of patients with metastatic colorectal cancer (mCRC). The trial will assess the safety and efficacy of onvansertib, in...

July 9, 2019

Developments

Titan Pharma and CVS Caremark enter Probuphine distribution agreement

Titan Pharmaceuticals (NASDAQ:TTNP) signed a specialty product distribution agreement with CVS Caremark, a subsidiary of CVS Health, further expanding access to treatment with Probuphine implant, Titan’s novel...

July 9, 2019

Executive Moves

IDEAYA Biosciences makes three appointments to management team

IDEAYA Biosciences (NASDAQ:IDYA) promoted Paul Stone to CFO, Andres Briseno to VP finance, and Mick O’Quigley to VP development operations. Continuing his role as IDEAYA’s principal financial and accounting...

July 9, 2019

Feature

Ocutrx augmented reality headset helping AMD patients see clearly

California-based Ocutrx Vision Technologies has developed an augmented reality (AR) headset that helps age-related macular degeneration (AMD) patients overcome severe and devastating vision loss.

July 9, 2019

Developments

Bellicum Pharma rivo-cel hits primary endpoint in pivotal trial

Bellicum Pharmaceuticals’ (NASDAQ:BLCM) registrational trial of rivo-cel achieved its primary endpoint of event-free survival when the drug was administered to patients receiving stem cell transplants.

July 8, 2019

Author - Abby Hardy

Aridis Pharma gets EMA orphan drug designation for CF drug

Alphatec launches titanium interbody implant for spinal fusion surgeries

Roth starts Akero Therapeutics at buy; PT $34

Rahul Sarugaser joins Raymond James’ life sciences research team

Stifel ups Rhythm Pharma to buy; PT held at $34

Trovagene initiates Phase 1b/2 trial of ovansertib in colorectal cancer

Titan Pharma and CVS Caremark enter Probuphine distribution agreement

IDEAYA Biosciences makes three appointments to management team

Ocutrx augmented reality headset helping AMD patients see clearly

Bellicum Pharma rivo-cel hits primary endpoint in pivotal trial

Subscribe